Legend Biotech
LEGN
50 hedge funds and large institutions have $753M invested in Legend Biotech in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 36 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.05% less ownership
Funds ownership: 9.32% → 9.27% (-0.05%)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
27% less capital invested
Capital invested by funds: $1.04B → $753M (-$283M)
35% less funds holding
Funds holding: 77 → 50 (-27)
75% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$30.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$23.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$18.1M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$12.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$15.5M |
| 2 |
TI
Think Investments
San Francisco,
California
|
-$13.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.87M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$8.25M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$7.76M |
LEGN Hedge Fund Activity: Q3 2020 in Review
50 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q3 2020, worth a combined $753M — down 27% from $1.04B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of LEGN and 9 opened new positions — a net loss of 27 holders — while 17 trimmed existing stakes and 16 added.
The largest buyer was Federated Hermes, adding an estimated $30.4M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $15.5M sold.
- 50 institutional investors held Legend Biotech (LEGN) as of Q3 2020, down from 77 in Q2 2020.
- Funds reported $753M of Legend Biotech stock for Q3 2020, down 27% quarter-over-quarter.
- 9 funds opened new Legend Biotech positions in Q3 2020 and 36 closed out, a net change of -27 holders.
- The largest Legend Biotech buyer in Q3 2020 was Federated Hermes, an estimated $30.4M added.
- The largest Legend Biotech seller in Q3 2020 was Driehaus Capital Management, an estimated $15.5M sold.
Based on aggregated 13F filings for Q3 2020.